SRR12475110
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.520
- OXIDATIVE_PHOSPHORYLATION+0.470
- E2F_TARGETS+0.450
- DNA_REPAIR+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.310
- G2M_CHECKPOINT+0.290
- FATTY_ACID_METABOLISM+0.210
- MTORC1_SIGNALING+0.150
- P53_PATHWAY+0.140
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- IL6_JAK_STAT3_SIGNALING-0.530
- TNFA_SIGNALING_VIA_NFKB-0.530
- HEDGEHOG_SIGNALING-0.510
- INFLAMMATORY_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.470
- COMPLEMENT-0.470
- TGF_BETA_SIGNALING-0.460
- ANGIOGENESIS-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.943 |
| 2 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.937 |
| 3 | C3L-00993 | — | cohortSQ1 | 0.933 |
| 4 | TCGA-5T-A9QA-01A-11R-A41B-07 | — | B | 0.926 |
| 5 | fea46737-a2b3-49d4-8358-d0737546b6da | — | — | 0.924 |
| 6 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.922 |
| 7 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.919 |
| 8 | 2d8cab40-0dda-4d6d-a9ba-83a82a7e1c15 | — | — | 0.918 |
| 9 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.916 |
| 10 | MNG87 | — | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |